HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.

Abstract
Approximately 30% of human cancers harbor oncogenic gain-of-function mutations in KRAS. Despite interest in KRAS as a therapeutic target, direct blockade of KRAS function with small molecules has yet to be demonstrated. Based on experiments that lower mRNA levels of protein kinases, KRAS-dependent cancer cells were proposed to have a unique requirement for the serine/threonine kinase STK33. Thus, it was suggested that small-molecule inhibitors of STK33 might have therapeutic benefit in these cancers. Here, we describe the development of selective, low nanomolar inhibitors of STK33's kinase activity. The most potent and selective of these, BRD8899, failed to kill KRAS-dependent cells. While several explanations for this result exist, our data are most consistent with the view that inhibition of STK33's kinase activity does not represent a promising anti-KRAS therapeutic strategy.
AuthorsTuoping Luo, Kristina Masson, Jacob D Jaffe, Whitney Silkworth, Nathan T Ross, Christina A Scherer, Claudia Scholl, Stefan Fröhling, Steven A Carr, Andrew M Stern, Stuart L Schreiber, Todd R Golub
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 109 Issue 8 Pg. 2860-5 (Feb 21 2012) ISSN: 1091-6490 [Electronic] United States
PMID22323609 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • BRD-8899
  • Biomarkers, Tumor
  • Isoquinolines
  • KRAS protein, human
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Small Molecule Libraries
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • STK26 protein, human
  • Protein Serine-Threonine Kinases
  • STK33 protein, human
  • Extracellular Signal-Regulated MAP Kinases
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
  • fasudil
Topics
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine (analogs & derivatives, pharmacology)
  • Biological Assay
  • Biomarkers, Tumor (metabolism)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Extracellular Signal-Regulated MAP Kinases (metabolism)
  • High-Throughput Screening Assays
  • Humans
  • Isoquinolines (chemistry, pharmacology)
  • Neoplasms (enzymology, pathology)
  • Phosphorylation (drug effects)
  • Protein Kinase Inhibitors (chemistry, pharmacology)
  • Protein Serine-Threonine Kinases (antagonists & inhibitors, metabolism)
  • Proteomics
  • Proto-Oncogene Proteins (metabolism)
  • Proto-Oncogene Proteins p21(ras)
  • Small Molecule Libraries (pharmacology)
  • ras Proteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: